Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial comparing exposure after single oral and intravenous doses of delafloxacin in volunteers

Trial Profile

Phase I trial comparing exposure after single oral and intravenous doses of delafloxacin in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delafloxacin (Primary) ; Delafloxacin (Primary)
  • Indications Gonorrhoea; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 12 Dec 2015 Results of this study and other two studies (n=94) published in the Clinical Therapeutics
    • 08 Oct 2014 New trial record
    • 11 Aug 2014 Complete results will be reported at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Melinta Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top